Bioxytran Initiates Research Collaboration with University of Georgia to Evaluate Drug Candidate’s Ability to Block H5N1 Bird Flu Virus
Bioxytran, Inc. (OTCQB: BIXT), a clinical-stage biotechnology company developing breakthrough antiviral treatments, today announced it has initiated a research collaboration
Read More